<DOC>
	<DOCNO>NCT00041964</DOCNO>
	<brief_summary>The purpose study find HIV-infected pregnant woman take anti-HIV drug increase amount HIV blood ( viral load ) baby . The purpose A5153s , substudy A5150 , characterize two anti-HIV drug ( nelfinavir [ NFV ] lopinavir/ritonavir [ LPV/r ] ) HIV-infected woman pregnancy childbirth . Sometimes pregnant woman increase HIV viral load baby bear . This study try find often happen . It also examine possible reason increase viral load occurs .</brief_summary>
	<brief_title>A Study HIV Levels During Pregnancy After Childbirth</brief_title>
	<detailed_description>Limited data suggest HIV-infected pregnant woman develop postpartum viral rebound . However , viral load change postpartum period adequately characterize . Changes adherence antiretroviral therapy , pregnancy-related change pharmacokinetics antiretroviral medication , decline immune competence mechanism postpartum viral load rebound may occur . This study design characterize incidence magnitude postpartum viral rebound initial 24 week postpartum explore mechanisms consequence viral rebound . Eligible patient evaluate gestational week 34 36 , delivery , regular visit 96 week postpartum . Most evaluation include medical history , physical exam , laboratory test , adherence quality-of-life questionnaire . Viral load CD4/CD8 cell count measure frequently . Patients expect receive least 8 week stable HAART delivery , continue HAART throughout remainder study . The choice HAART leave primary provider . No antiretroviral drug provide study . Patients participate A5153s substudy receive either NFV LPV/r part HAART . Pharmacokinetic blood sample take place 36 week gestation , 6 week postpartum , 24 week postpartum . Patients record administration time dose NFV LPV/r 48 hour prior substudy visit , hold regularly schedule dose antiretroviral medication substudy day . Patients arrive clinic fasting ( food drink previous 8 hour ) give standardize breakfast prior supervise administration NFV LPV/r dose . An intravenous catheter place arm vein blood collection pre-dose 1 , 2 , 4 , 6 hour post-dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are age 13 older . Are 22 30 week pregnant . Have pregnancy confirm ultrasound 14 week gestation later . Are infected HIV . Are plan receive least 8 week highly active antiretroviral therapy ( HAART ) time baby . Are available followup duration study . Exclusion Criteria Patients may eligible study : Intend terminate pregnancy . Intend breastfeed baby . Are carry baby major abnormality , include spina bifida , anencephaly , hydrops , ascites . Have take certain medication . Are enrolled study require large blood draw . Will take antiHIV drug prevent mothertochild transmission HIV , treat maternal infection . Actively abuse drug alcohol way would interfere participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lopinavir</keyword>
	<keyword>Pregnancy Trimester , Third</keyword>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Viral Load</keyword>
	<keyword>puerperium</keyword>
</DOC>